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Abstract
Background: Although free radicals have been reported to play a role in the expansion of ischemic brain lesions,
the effect of free radical scavengers is still under debate. In this study, the temporal profile of ischemic stroke
lesion sizes was assessed for more than one year to evaluate the effect of edaravone which might reduce ischemic
damage.
Methods: We sequentially enrolled acute ischemic stroke patients, who admitted between April 2003 and March
2004, into the edaravone(-) group (n = 83) and, who admitted between April 2004 and March 2005, into the
edaravone(+) group (n = 93). Because, edaravone has been used as the standard treatment after April 2004 in our
hospital. To assess the temporal profile of the stroke lesion size, the ratio of the area [T2-weighted magnetic
resonance images (T2WI)/iffusion-weighted magnetic resonance images (DWI)] were calculated. Observations on
T2WI were continued beyond one year, and observational times were classified into subacute (1-2 months after the
onset), early chronic (3-6 month), late chronic (7-12 months) and old (≥13 months) stages. Neurological deficits
were assessed by the National Institutes of Health Stroke Scale upon admission and at discharge and by the
modified Rankin Scale at 1 year following stroke onset.
Results: Stroke lesion size was significantly attenuated in the edaravone(+) group compared with the edaravone(-)
group in the period of early and late chronic observational stages. However, this reduction in lesion size was
significant within a year and only for the small-vessel occlusion stroke patients treated with edaravone. Moreover,
patients with small-vessel occlusion strokes that were treated with edaravone showed significant neurological
improvement during their hospital stay, although there were no significant differences in outcome one year after
the stroke.
Conclusion: Edaravone treatment reduced the volume of the infarct and improved neurological deficits during the
subacute period, especially in the small-vessel occlusion strokes.
Background
Acute treatment of ischemic stroke requires a quick
response after the onset of the injury; for example,
thrombolytic therapy using recombinant tissue-type
plasminogen activator was effective when applied within
3 hours of onset to be effective in US and Japan [1], and
4.5 hrs in Europe [2,3]. Inflammatory responses and
injury to the endothelia of blood vessels have been
simultaneously observed in acute ischemic lesions [4,5].
Therefore, it is critical not only to restore blood flow
but also to protect neurons in order to reduce brain
damage following an ischemic insult. Moreover, an
extension of the therapeutic window would be beneficial
to treat a broader range of patients with acute brain
ischemia [6,7].
A somewhat novel line of therapy used to treat
ischemic stroke is the use of free radical quenching
agents [8]. Edaravone, a free radical scavenger, has been
clinically available in Japan since 2001 and has been
reported to improve clinical outcomes in patients exhi-
biting ischemic strokes [9]. Experimental studies have
revealed that the possible mechanisms of edaravone are
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any medium, provided the original work is properly cited.decreasing oxidative stress [10], protecting neurovascu-
lar units [11,12], and reducing the activation of micro-
glia [13] after ischemic stress. Since most published
studies have focused on the effect of edaravone during
the acute therapeutic stages of cerebral ischemia, it is
unclear if edaravone is effective in the chronic stages of
cerebral ischemia. Therefore, we set out to determine if
there are any changes in lesion size with edaravone
treatment during the acute and chronic phases following
cerebral ischemia and to explore whether the expansion
of ischemic lesion was dependent on a free radical
scavenging.
Methods
Patients
The use of edaravone for the treatment of cerebral
ischemia at our hospital was extremely limited prior to
March 2004. Upon approval of its use by the Medical
Ethics Committee in April 2004, edaravone was readily
available as a therapeutic agent against cerebral strokes.
This study designed to examine the use of edaravone
and the outcomes following stroke was approved by
the Medical Ethics Committee in Research Institute for
Brain & Blood Vessels -Akita. Patients admitted to the
hospital within 24 hs after onset with a diagnosis of
a c u t ei s c h e m i cs t r o k eb e t w e e nA p r i l2 0 0 3a n dM a r c h
2004 were treated with standard medications without
edaravone, and these patients were classified into an
edaravone-untreated group [edaravone(-) group; n =
83]. Similarly, patients admitted between April 2004
and March 2005 were treated with standard medica-
tions in addition to an edaravone intravenous drip
infusion (Radicut
®, Mitsubishi Tanabe Pharma Cor-
poration, Tokyo, Japan: 30 mg twice a day, which was
the dosage approved by Japanese Ministry of Health,
Labour and Welfare), and these patients were classified
into an edaravone-treated group [edaravone(+) group;
n = 93]. All patients were clinically diagnosed with
ischemic stroke, which was confirmed by magnetic
resonance imaging (MRI: Sigma1.5T, GE Medical Sys-
tems) on admission. Transverse T2-weighted images
(T2WI, TR: 3600 sec, TE: 96 sec) and diffusion-
weighted images (DWI, TR: 5800 sec, TE: 76.2 sec)
were acquired with a slice thickness of 5 mm. Mag-
netic resonance angiography (MRA) was performed
using the three-dimensional time-of-flight method, and
images were rendered using the maximum intensity
projection method. All patients were categorized into
four groups according to the classification of their
stroke subtype by the Trial of Org 10172 in Acute
Stroke Treatment (TOAST) [14]: cardioembolism,
large-artery atherosclerosis, small-vessel occlusion and
others. Ischemic stroke patients with unknown etiology
were excluded from this study.
The ischemic lesion at onset was observed based on
the findings of the DWI-positive area which was con-
firmed by the apparent diffusion coefficient (ADC) map.
The lesion in the later phases was assessed by the find-
ings of the T2WI-positive area. The maximum lesion
size in a single slice was adapted to the calculation
according to a previously reported method [15]. The
measurement of the slices was performed by the assis-
tance of a computer software program (Synapse 3.1.1,
Fujifilm Medical Systems USA Inc.). To evaluate the
temporal profile of the stroke lesion, the ratio of the
lesion size at a later period against the onset lesion size
(T2WI/DWI) was calculated. The average ratio was
assessed several times after the onset: subacute period
(1-2 months), early chronic period (3-6 months), late
chronic (7-12 months) and old (≥13 months) periods.
In addition to infarct sizes, several other factors were
compared between the edaravone(+) and edaravone(-)
groups. The National Institutes of Health Stroke Scale
(NIHSS) was used to evaluate the neurological deficits
of the patients upon admission for the cerebral stroke
as well as at the time of discharge. The duration of
in-hospital treatment was also analyzed. The activity of
daily living (ADL) level was assessed at 1 year following
stroke onset based on patients’ clinical records and eval-
uated using the modified Rankin Scale (mRS).
Statistical analysis
All data in the graphs are expressed as means ± SD.
Patients’ backgrounds were compared between the edar-
avone(-) and edaravone(+) groups using Unpaired Stu-
dent’s t-test. The relationship oft h ea l t e r a t i o n so ft h e
lesion size ratio to elapsed time was assessed by simple
regression analysis. A nonparametric Mann-Whitney’sU
test was used for the analysis of the difference of the
average lesion size ratio between the edaravone(-) and
edaravone(+) groups at the same periods.
Nonparametric Kruskal-Wallis test was used for com-
parison of the difference of mRS distribution between
edaravone(-) and edaravone(+) groups. All calculations
were performed by the assistance of computer software
(Stat View J 5.0. SAS Institute Inc., Cary, NC). Values of
p < 0.05 were considered significant.
Results
Clinical backgrounds
There were no statistically significant differences of
background data, including age, sex and clinical risks
between the edaravone(-) and edaravone(+) groups at
onset of the ischemic insult (Table 1). Moreover, the
distribution of stroke subtypes, the average lesion size
and the neurological severity at onset were also not sig-
nificantly different between the edaravone(-) and edara-
vone(+) groups (Table 2).
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The temporal profiles of the stroke lesions were ana-
lyzed and plotted (Figure 1). The regression lines indi-
cated that stroke lesions in the edaravone(+) group were
r e d u c e da taq u i c k e rr a t et h a nt h a ti nt h ee d a r a v o n e ( - )
group (Figure 1A). The reduction in the size of the
stroke lesion was significant in the edaravone(+) group
compared with the edaravone(-) group within the first12
months (Figure 1B). When patients were classified into
observational times, there was a significant difference
between the edaravone(+) and edaravone(-) groups in
the subactute (1-2 months; p = 0.006), early chronic
(3-6 months; p = 0.012) and late chronic (7-12 months;
p = 0.001) periods, but not in the old (≥13 months; p >
0.05) period.
Subsequently, we examined the temporal profiles of the
ischemic lesions based on stroke subtypes. There were
no significant differences between the regression lines or
lesion sizes between the edaravone(-) and edaravone(+)
groups at any of the observational times for strokes
attributed to cardioembolism (Figure 2A, B) or large-
artery atherosclerosis (Figure 2C, D). However, the exam-
ination of strokes attributed to small-vessel occlusion
revealed that edaravone treatment caused a significant
r e d u c t i o ni nl e s i o n sa tt h es u b a c u t e( 1 - 2m o n t h s ;p=
0.001) and late chronic (7-12 months; p = 0.014) periods,
but not at the early chronic or old periods (Figure 2E, F).
ADL assessment
As shown in Table 2, there was no significant difference
in the duration of hospitalization between the edaravone
Table 1 Patients’ backgrounds at onset
Edaravone(-)
(n = 83)
Edaravone(+)
(n = 93)
Female (%) 29 (35) 28 (30)
Age (years old) 69.9 ± 10.67 67.2 ± 10.49
Hypertension (n, %) 48 (57.8) 62 (66.7)
Hyperlipidemia (n, %) 22 (26.5) 34 (36.6)
Diabetes Mellitus (n, %) 23 (27.7) 25 (26.9)
Smoking (n, %) 30 (36.1) 36 (38.7)
Alcohol drinking (n, %) 36 (43.4) 35 (37.6)
Atrial fibrillation (n, %) 18 (21.7) 17 (18.3)
Table 2 Clinical data on admission and at discharge in
each stroke subtype
Edaravone(-)
(n = 83)
Edaravone(+)
(n = 93)
Cardioembolism (%) 28 (33.7) 21 (22.6)
Average lesion size (mm
2) 1359.8 ± 1174.1 1391.3 ± 865.9
Hospital duration (days) 39.5 ± 52.1 36.2 ± 21.4
NIHSS on admission① 6.9 ± 6.2 6.6 ± 6.4
at discharge② 4.6 ± 5.6 6.9 ± 10.5
Improvement rate (①-②) 2.8 ± 3.6 -0.1 ± 9.2
Large-artery (%) 30 (36.1) 38 (40.9)
Average lesion size (mm
2) 251.9 ± 285.6 235.1 ± 136.6
Hospital duration (days) 24.8 ± 15.2 27.6 ± 25.2
NIHSS on admission① 3.8 ± 3.7 4.0 ± 4.6
at discharge② 2.3 ± 2.8 2.4 ± 3.7
Improvement rate (①-②) 1.6 ± 3.4 1.6 ± 3.2
Small-vessel (%) 25 (30.1) 34 (36.6)
Average lesion size (mm
2) 67.9 ± 37.2 77.6 ± 40.4
Hospital duration (days) 20.8 ± 12.6 21.8 ± 14.4
NIHSS on admission① 2.2 ± 2.2 4.1 ± 4.6
at discharge② 1.4 ± 1.6 2.1 ± 3.2
Improvement rate (①-②) 0.8 ± 1.0 2.0 ± 2.8 ‡
NIHSS: National Institutes of Health Stroke Scale.
‡: p < 0.05
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Figure 1 Alteration of the lesion size. A: Scatter graphs of the
ratios (T2WI/DWI) of edaravone(-) group (open circle) and
edaravone(+) group (closed circle). B: The average ratio in
edaravone(-) group (white bar) and edaravone(+) group (black bar)
in 1-2 months, 3-6 months, 7-12 months and ≥13 months. The
regression lines indicate in dotted line as edaravone(-) group (y =
1.10-0.03x, R
2 = 0.11, p = 0.001) and in black line as edaravone(+)
group (y = 0.78-0.01x, R
2 = 0.04, p = 0.031). The average ratio is
significantly lower in the edaravone(+) group compared with
edaravone(-) group in 1-2 months, 3-6 months and 7-12 months.
*: p < 0.05, **: p < 0.01.
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Figure 2 Alteration of the lesion size by different stroke subtypes. Scatter graphs of the ratios (T2WI/DWI) of edaravone(-) group (open
circle) and edaravone(+) group (closed circle) in cardioembolism (A), large-artery atherosclerosis (C) and small-vessel occlusion (E) stroke
subtypes. Average ratios of edaravone(-) group (white bar) and edaravone(+) group (black bar) in the cardioembolism (B), the large-artery
atherosclerosis (D) and the small-vessel occlusion (F). Number of cases is indicated in the bar. The regression lines indicate in dotted line as
edaravone(-) group and in black line as edaravone(+) group (the formula of cardioembolism: y = 1.07-0.14x, R
2 = 0.53, p = 0.160 and y = 0.82-
0.004x, R
2 = 0.003, p = 0.786, respectively; the formula of large-artery atherosclerosis: y = 1.10-0.03x, R
2 = 0.14, p = 0.028 and y = 0.81-0.01x, R
2 =
0.03, p = 0.205, respectively; the formula of small-vessel occlusion: y = 1.18-0.32x, R
2 = 0.14, p = 0.054 and y = 0.68-0.02x, R
2 = 0.20, p = 0.007,
respectively). In the small-vessel occlusion, the reduction of lesion size is earlier in edaravone(+) group compared with edaravone(-) group. There
are significant differences of the average ratios between edaravone(-) and edaravone(+) groups in 1-2 months and 7-12 months in the small-
vessel occlusion. *: p < 0.05 and **: p < 0.01.
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Page 4 of 7(-) and edaravone(+) groups among different stroke sub-
types. In addition, there was no significant difference in
neurological deficits at the time of discharge, as assessed
by the NIHSS. If the improvement rate was calculated
by the difference in the NIHSS scores of each patient
(NIHSS on admission - NIHSS at discharge), the edara-
vone(+) group of the small-vessel occlusion stroke sub-
type showed significant improvement compared with
the edaravone(-) group (p = 0.0465). Moreover, the
long-term prognosis (1 year after the stroke) was evalu-
ated using the mRS score. As depicted in Figure 3, there
was no significant difference in the mRS distributions
between the edaravone(-) and edaravone(+) groups.
Even in small-vessel occlusion, which showed a faster
reduction of lesion size with edaravone treatment,
showed no significant difference in mRS distribution
between the edaravone(+) and edaravone(-) groups.
Discussion
Previous studies have revealed that the free radical sca-
venger, edaravone, is neuroprotective following acute
ischemic stroke in both animal and human models
[9,10]. Moreover, the protective effect of edaravone
against oxidative stress has been reported to not be lim-
ited to neurons, but to also extend to astrocytes and
endothelial cells. Thus, edaravone treatment results in
protection of the neurovascular unit [11,12]. In the EDO
study, edaravone reduced the incidence of recurrent
stroke following acute treatment compared with the
anti-platelet drug, sodium ozagrel [16]. However, a
recent trial with NXY-059, another free radical scaven-
ger, showed no significant neuroprotection when
administered to stroke patients (SAINT II) [17]. Collec-
tively, these findings suggest that edaravone may have
efficacy in ischemic stroke treatment, but with limita-
tions in its therapeutic capability [18].
In our study, patients treated with edaravone exhibited
a significant reduction in ischemic lesion size compared
with those not treated with edaravone. However, this
finding was limited to specific time frames, or the suba-
cute, early chronic and late chronic phases. Generally,
edaravone is administrated twice a day for 2 weeks from
the onset of the ischemic insult. Because of its ability to
restrict inflammation, edaravone may potentially limit
the ischemic insult during the early phases and, thus,
restrict the expansion of the stroke lesion faster than
those not treated with the free radical scavenger. In sup-
port of this finding, edaravone has been reported to
reduce delayed neuronal death after middle cerebral
artery occlusion by limiting N-acetyl aspartate signaling
in humans [19]. Further supporting our findings, brain
edema following stroke with internal carotid artery ste-
nosis has also been reported to be limited to the acute
period if patients were treated with edaravone [20].
Upon closer examination of our results, lesion reduc-
tion elicited by edaravone was most effective in the
small-vessel occlusion stroke subtype. In this study,
lesions due to small-vessel occlusion were mostly
located in corona radiata (white matter) and some were
in basal ganglia (gray matter). Anatomically, white mat-
ter contains more astrocytes and microglia which parti-
cipate in the inflammatory response, and more
phospholipids which are vulnerable to oxidative stress
[21]. Therefore, it is reasonable that edaravone treat-
ment excerted a significant effect on the small-vessel
occlusion subtype due to its actions on inflammation.
Actually, a recent study reported that edaravone reduced
the extent of damage in both the gray and white matter
caused by global ischemia [22], supporting the theory
that edaravone may act by limiting inflammation.
While effective in the small-vessel occlusion stroke
subtype, edaravone failed to elicit statistically significant
reductions in lesion sizes in the cardioembolism and the
large-artery atherosclerosis subtype groups in our study.
It is possible that reductions of lesional expansion by
edaravone may be limited by the hemodynamic worsen-
ing, which occurs in these specific stroke subtypes.
Moreover, because our data included patients with both
mild and severe neurological deficits, the effects of edar-
avone may be masked by its inability to treat ischemic
insults unconditionally. In support of this notion, it has
been reported that edaravone improves the outcome of
embolic strokes only in patients with mild neurological
deficits [23]. Furthermore, edaravone treatment
appeared to trend towards lesion size reductions in all
s u b t y p e s ,a n dn o tj u s tt h es m a ll-vessel occlusion stroke
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Figure 3 Neurological outcome. The distribution of each mRS at
one year after the onset. The number of patients is shown in the
columns. There is no difference of the distribution of the outcome
in total analysis. When only small-vessel occlusion is observed, the
percentage of mRS 1 in edaravone(+) group seems increased,
although there is no statistical difference between edaravone(-) and
edaravone(+) groups.
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Page 5 of 7subtype, suggesting that the small sample sizes in this
study may have prevented the identification of statistical
significance between the treatment groups. This was
overcome when the stroke subtypes were grouped
collectively.
Our findings indicate that treatment with edaravone
did not cause any significant differences in clinical out-
comes, such as the NIHSS at discharge point, duration of
hospital days, and the mRS at one year after the onset.
However, a significant improvement in clinical outcome
at discharge was observed in the small-vessel occlusion
stroke subtype treated with edaravone. These findings are
supported by a recent study on acute lacunar infarctions
in which Ohta et al. found that a protective effect of edar-
avone was not identified using NIHSS scores but could
be identified when using palsy scores [24].
A limitation of our study is that we examined a retro-
spective cohort that was gathered from a two year per-
iod, and the patients were consecutively treated
according to the typical treatment regimens with and
without edaravone, as described in the methods section.
A fully-powered, prospective, randomized control trial
may expand on our findings and demonstrate the full
benefits of edaravone in patients with ischemic insults.
Indeed, current clinical trials are being conducted with
free radical scavengers, including a study of the safety
and pharmacokinetics of MCI-186 in subjects with acute
ischemic stroke in Europe [25].
Conclusion
Edaravone can effectively reduce the size of ischemic
stroke lesions and improve neurological deficits in
patients with small-vessel occlusion, i.e., lacunar infarc-
tion. Further studies are needed to identify the true ben-
efits and limitations of this free radical scavenger in
cerebral ischemia.
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